Tag: Cancer: Breast
Response to Neoadjuvant Endocrine Therapy for Breast Cancer May Vary by Race
Race is a significant predictor of downstaging in HR+ breast cancer after adjustment for duration of NET, clinical stage
AI Assistance May Improve Accuracy of Breast Cancer Screening
Sensitivity increased for subgroups with small lesion sizes, invasive carcinomas
Batwing Mastopexy Performed in Immediate Breast Reconstruction
Complication rates comparable for women receiving concurrent batwing mastopexy, standard implant-based reconstruction
More Physical Activity, Less Sitting May Cut Breast Cancer Risk
Lifelong physical activity or sedentary time, assessed by genotype, may be associated with risk for breast cancer
Fertility Preservation Not Linked to Relapse, Mortality in Breast Cancer
Adjusted rate of disease-specific mortality and relapse similar for those with and without exposure to hormones
Postop Breast MRI Features May Predict Risk for Second Breast Cancer
Background parenchymal enhancement at surveillance breast MRI linked to increased risk for future second breast cancer
Cancer-Related Fatigue in Women With Breast Cancer May Affect Balance
Greater CRF predicts increased pre- and postexertional static sway, while chemo-induced peripheral neuropathy does not
Efficacy of Durvalumab for Early-Stage TNBC Examined by Race
In Phase I/II trial of durvalumab with neoadjuvant chemo, pathological complete response rates similar for Black, non-Black patients
Diet High in n-3-PUFAs Linked to Lower Breast Cancer Risk
Higher intake of marine n-3 PUFAs and total n-3 PUFAs associated with lower risk for breast cancer, especially for premenopausal women
FDA Approves First Targeted Therapy for HER2-Low Breast Cancer
HER2-low is a new classification for a subset of HER2-negative breast cancer
